Objective This study examined whether cerebrospinal fluid (CSF) baseline levels of the
synaptic protein NPTX2 predict time to onset of symptoms of mild cognitive impairment …

Memory loss in Alzheimer's disease (AD) is attributed to pervasive weakening and loss of
synapses. Here, we present findings supporting a special role for excitatory synapses …

Introduction: Biomarkers that reflect pathologic processes affecting neuronal function during
preclinical and early stages of Alzheimer's disease (AD) are needed to aid drug …

Background Alzheimer's disease (AD) is the major cause of death in adults with Down
syndrome (DS). There is an urgent need for objective markers of AD in the DS population to …

Abstract Introduction Amyloid, Tau, and neurodegeneration biomarkers can stage
Alzheimer's Disease (AD). Synaptic biomarkers may help track cognition. Methods In …

Background Alzheimer's disease (AD) is the most prevalent form of dementia. Currently, the
most studied biomarkers of AD are cerebrospinal fluid (CSF) amyloid β 1-42, total tau and …

Background: Alzheimer's disease (AD) is the most common type of dementia, with
progressive onset of clinical symptoms. The main pathological hallmarks are brain deposits …

Chronic neuroinflammation is thought to potentiate medial temporal lobe (MTL) atrophy and
memory decline in Alzheimer's disease (AD). It has become increasingly important to find …

Abstract Objective Neuronal Pentraxin 2 (NPTX2) has recently been widely reported as a
novel biomarker for Alzheimer's disease (AD), but its correlation with vascular dementia …

Background: Dementia with Lewy bodies (DLB) is a neurodegenerative disease where
synaptic loss and reduced synaptic integrity are important neuropathological substrates …